 | Up a level |
Bourhis, J.; Le Tourneau, C.; Calderon, B.; Martin, L.; Sire, C.; Pointreau, Y.; Ramee, J-F.; Coutte, A.; Boisselier, P.; Kaminsky-Forrett, M-C.; Delord, J-P.; Clatot, F.; Sun, X.; Villa, J.; Magne, N.; Eliçin, O; Damstrup, L.; Gollmer, K.; Crompton, P. and Tao, Y. (2022). LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study. Annals of oncology, 33(S7), S1400-S1400. Elsevier 10.1016/j.annonc.2022.08.030
